TG Therapeutics Inc

19 oct. 2026, 20:07 UTC

Shares of TG Therapeutics Inc are declining, finishing well below the 20-day moving average and near the lower end of the one-month range.

16 oct. 2026, 19:53 UTC

TG Therapeutics Inc shares are declining sharply, trading well below their 20-day moving average and near the lower end of their one-month range.

15 oct. 2026, 20:07 UTC

TG Therapeutics Inc shares advanced, peaking in the late morning and settling near the day's high, remaining above its 20-day moving average.

14 oct. 2026, 23:21 UTC

TG Therapeutics Inc shares declined in after-market trading, moving lower alongside the broader market amid significant declines in technology stocks and rising crude oil prices.

12 oct. 2026, 19:56 UTC

TG Therapeutics published a five-year study showing BRIUMVI has a lower risk of disability progression compared to ocrelizumab and ofatumumab in relapsing multiple sclerosis.

10 oct. 2026, 00:01 UTC

TG Therapeutics Inc shares are trading modestly higher in after-market hours, continuing a trend of four consecutive sessions finishing higher.

9 oct. 2026, 23:20 UTC

TG Therapeutics Inc shares are trading modestly lower in after-market hours, having fluctuated between a decline and a slight gain since Friday's close.

8 oct. 2026, 19:15 UTC

TG Therapeutics schedules the 10th Joint ACTRIMS-ECTRIMS Meeting for October 21-23, 2026, to present initial clinical results of Azer-Cel and BRIUMVI data.

7 oct. 2026, 20:01 UTC

TG Therapeutics Inc is trading higher, having previously peaked earlier in the session before pulling back, and remains below its 20-day moving average.

6 oct. 2026, 20:00 UTC

TG Therapeutics Inc shares fell sharply, reaching an early high before declining significantly, remaining well below its 20-day moving average.

5 oct. 2026, 20:06 UTC

TG Therapeutics Inc. shares fell sharply, pulling back from Friday's close after earlier reaching a session high, amid multiple year-end catalysts.

2 oct. 2026, 19:26 UTC

TG Therapeutics is trading higher amid social media buzz over a buy recommendation and an $86 price target for its anti-CD20 treatment, Briumvi.

1 oct. 2026, 23:05 UTC

TG Therapeutics Inc is trading modestly higher in after-market hours, despite remaining below its 20-day moving average after three consecutive sessions finishing lower.

30 sept. 2026, 20:07 UTC

TG Therapeutics Inc shares fell modestly following Tuesday's close, amid a broader market decline, and are currently near the midpoint of their one-month trading range.

28 sept. 2026, 20:07 UTC

TG Therapeutics Inc shares are declining, continuing a downward trend since Friday's close amid a broader market downturn, despite a brief recovery attempt.

25 sept. 2026, 21:01 UTC

TG Therapeutics Inc declined in after-market trading, reversing an initial uptick and moving lower from Friday's close, despite remaining above its 20-day moving average.

24 sept. 2026, 23:45 UTC

TG Therapeutics Inc declined in after-market hours on Thursday, moving from a larger drop to a more modest decrease while remaining above its 20-day moving average.

23 sept. 2026, 23:01 UTC

TG Therapeutics Inc declined in after-market trading, reversing an initial uptick, despite strong U.S. economic data indicating robust growth in the private sector.

22 sept. 2026, 22:06 UTC

TG Therapeutics Inc saw a slight decline in after-market trading, despite recent strength, as economic data showed a contraction in manufacturing activity.

21 sept. 2026, 19:16 UTC

TG Therapeutics shares are advancing as discussions highlight BRIUMVI's growing momentum and market share gains in the IV anti-CD20 market for relapsing multiple sclerosis.

18 sept. 2026, 20:06 UTC

TG Therapeutics is trading modestly higher, rebounding after an earlier pullback, and has now finished higher for three consecutive sessions.

17 sept. 2026, 19:54 UTC

TG Therapeutics Inc is moving higher as economic data shows unexpected labor market strength, despite a decline in housing starts.

16 sept. 2026, 23:56 UTC

TG Therapeutics Inc is trading lower in after-market hours, retracing from an initial high shortly after the market closed, despite remaining above its 20-day moving average.

15 sept. 2026, 23:41 UTC

TG Therapeutics shares are lower in after-market trading amid negative market sentiment. The New York Empire State Manufacturing Index fell sharply, raising investor caution.

14 sept. 2026, 19:16 UTC

TG Therapeutics Inc shares are lower today amid broader market declines. CEO Weiss highlighted upcoming catalysts, including a significant treatment administration method.

11 sept. 2026, 20:08 UTC

TG Therapeutics shares are declining during Friday's session, despite social media optimism about its subcutaneous BRIUMVI formulation and potential Priority Review Voucher benefits.

10 sept. 2026, 20:31 UTC

TG Therapeutics Inc shares are lower in after-market trading, reflecting a decline despite starting the session near the top of their one-month range.

9 sept. 2026, 20:07 UTC

TG Therapeutics shares are lower today amid cautious outlook from CEO Weiss and mixed analyst sentiment on sales estimates. Earlier, the stock pulled back from session highs.

4 sept. 2026, 20:07 UTC

TG Therapeutics Inc is declining amid increased selling pressure in risk assets following a strong jobs report raising monetary policy concerns.

3 sept. 2026, 20:07 UTC

TG Therapeutics will participate in the Cantor Global Healthcare Conference. Shares are lower today, despite earlier gains and positive sentiment surrounding the company.